In an effort to prevent opioid overdose mortality among Veterans, Department of Veterans Affairs (VA) facilities began implementing opioid overdose education and naloxone distribution (OEND) in 2013 and a national program began in 2014. VA is the first national health care system to implement OEND. The goal of this study is to examine patient perceptions of OEND training and naloxone kits.
Methods
Four focus groups were conducted between December 2014 and February 2015 with 21 patients trained in OEND. Participants were recruited from a VA residential facility in California with a substance use disorder treatment program (mandatory OEND training) and a homeless program (optional OEND training). Data were analyzed using matrices and open and closed coding approaches to identify participants’ perspectives on OEND training including benefits, concerns, differing opinions, and suggestions for improvement.
Results
Veterans thought OEND training was interesting, novel, and empowering, and that naloxone kits will save lives. Some veterans expressed concern about using syringes in the kits. A few patients who never used opioids were not interested in receiving kits. Veterans had differing opinions about legal and liability issues, whether naloxone kits might contribute to relapse, and whether and how to involve family in training. Some veterans expressed uncertainty about the effects of naloxone. Suggested improvements included active learning approaches, enhanced training materials, and increased advertisement.
Conclusions
OEND training was generally well received among study participants, including those with no indication for a naloxone kit. Patients described a need for OEND and believed it could save lives. Patient feedback on OEND training benefits, concerns, opinions, and suggestions provides important insights to inform future OEND training programs both within VA and in other health care settings. Training is critical to maximizing the potential for OEND to save lives, and this study includes specific suggestions for improving the effectiveness and acceptability of training.
HedegaardH, ChenL, WarnerM. Drug-Poisoning Deaths Involving Heroin: United States, 2000–2013. NCHS Data Brief, no 190. Available at: http://www.cdc.gov/nchs/data/databriefs/db190.pdf. Published 2015. Accessed August 1, 2015.
3.
LeviJ, SegalL, MartinA. The Facts Hurt: A State-By-State Injury Prevention Policy Report 2015. Washington, DC: Trust for America's Health, Robert Wood Johnson Foundation; 2015.
4.
ChenLH, HedegaardH, WarnerM. Rates of deaths from drug poisoning and drug poisoning involving opioid analgesics—United States 1999–2013. MMWR Morb Mortal Wkly Rep. 2015;64:32.
5.
BohnertAS, IlgenMA, GaleaS, McCarthyJF, BlowFC. Accidental poisoning mortality among patients in the Department of Veterans Affairs Health System. Med Care. 2011;49:393–396.
6.
ComptonWM, VolkowND, ThrockmortonDC, LurieP. Expanded access to opioid overdose intervention: research, practice, and policy needs. Ann Intern Med. 2013;158:65–66.
7.
US Department of Health and Human Services. Actions to address opioid-drug-related overdoses and deaths. J. Pain Palliat Care Pharmacother. 2015;29:133–139.
8.
Substance Abuse and Mental Health Services Administration. SAMHSA Opioid Overdose Prevention Toolkit. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2013. HHS Publication No. (SMA) 13-4742.
9.
United Nations Office on Drugs and Crime. Opioid Overdose: Preventing and Reducing Opioid Overdose Mortality. New York: United Nations; 2013.
10.
World Health Organization. Community Management of Opioid Overdose. Geneva, Switzerland: World Health Organization; 2014.
11.
SealKH, DowningM, KralAH, . Attitudes about prescribing take-home naloxone to injection drug users for the management of heroin overdose: a survey of street-recruited injectors in the San Francisco Bay Area. J Urban Health. 2003;80:291–301.
12.
StrangJ, ManningV, MayetS, . Overdose training and take-home naloxone for opiate users: prospective cohort study of impact on knowledge and attitudes and subsequent management of overdoses. Addiction. 2008;103:1648–1657.
13.
MaxwellS, BiggD, StanczykiewiczK, Carlberg-RacichS. Prescribing naloxone to actively injecting heroin users: a program to reduce heroin overdose deaths. J Addict Dis. 2006;25:89–96.
14.
PiperTM, StancliffS, RudenstineS, . Evaluation of a naloxone distribution and administration program in New York City. Subst Use Misuse. 2008;43:858–870.
15.
SealKH, ThawleyR, GeeL, . Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study. J Urban Health. 2005;82:303–311.
16.
TobinKE, ShermanSG, BeilensonP, WelshC, LatkinCA. Evaluation of the Staying Alive programme: training injection drug users to properly administer naloxone and save lives. Int J Drug Policy. 2009;20:131–136.
17.
WagnerKD, ValenteTW, CasanovaM, . Evaluation of an overdose prevention and response training programme for injection drug users in the Skid Row area of Los Angeles, CA. Int J Drug Policy. 2010;21:186–193.
Role of Naloxone in Opioid Overdose Fatality Prevention. Food and Drug Administration, Center for Drug Evaluation and Research, Office of the Assistant Secretary for Health, National Institute on Drug Abuse; and the Centers for Disease Control and Prevention. http://www.fda.gov/Drugs/NewsEvents/ucm277119.htm. Public Workshop. April 12, 2012.
21.
WalleyAY, XuanZ, HackmanHH, . Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013;346:f174.
22.
CoffinPO, SullivanSD. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. Ann Intern Med. 2013;158:1–9.
23.
BeletskyL, RuthazerR, MacalinoGE, RichJD, TanL, BurrisS. Physicians’ knowledge of and willingness to prescribe naloxone to reverse accidental opiate overdose: challenges and opportunities. J Urban Health. 2007;84:126–136.
24.
BinswangerIA, KoesterS, MuellerSR, GardnerEM, GoddardK, GlanzJM. Overdose education and naloxone for patients prescribed opioids in primary care: a qualitative study of primary care staff. J Gen Intern Med. 2015; 30(12):1837-44. doi:10.1007/s11606-015-3394-3
25.
CoffinPO, FullerC, VadnaiL, BlaneyS, GaleaS, VlahovD. Preliminary evidence of health care provider support for naloxone prescription as overdose fatality prevention strategy in New York City. J Urban Health. 2003;80:288–290.
26.
MathesonC, Pflanz-SinclairC, AucottL, . Reducing drug related deaths: a pre-implementation assessment of knowledge,barriers and enablers for naloxone distribution through general practice. BMC Fam Pract. 2014;15:12. doi:10.1186/1471-2296-15-12
27.
NealeJ, StrangJ. Naloxone-does over-antagonism matter? Evidence of iatrogenic harm after emergency treatment of heroin/opioid overdose. Addiction. 2015;110(10):1644-52. doi:10.1111/add.13027
28.
GreenTC, BowmanSE, RayM, McKenzieM, LordSE, RichJD. Development of an incarceration-specific overdose prevention video: Staying Alive on the Outside. Health Educ J. 2015;74:627–637.
29.
StetlerCB, DamschroderLJ, HelfrichCD, HagedornHJ. A guide for applying a revised version of the PARIHS framework for implementation. Implement Sci. 2011;6:99.
30.
MorganDL.The Focus Group Guidebook. Thousand Oaks, CA: Sage Publications; 1997.
31.
Miles MB, Huberman AM, Saldaña J. Qualitative Data Analysis: A Methods Sourcebook. Thousand Oaks, CA: Sage Publications; 2013.
32.
MosherHJ, KrebsEE, CarrelM, KaboliPJ, WegMW, LundBC. Trends in prevalent and incident opioid receipt: an observational study in Veterans Health Administration 2004–2012. J Gen Intern Med. 2015;30:597–604.
33.
BohnertAS, ValensteinM, BairMJ, . Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011;305:1315–1321.
34.
DavoliM, BargagliAM, PerucciCA, . Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study. Addiction. 2007;102:1954–1959.
35.
GossopM, GreenL, PhillipsG, BradleyB. Lapse, relapse and survival among opiate addicts after treatment. A prospective follow-up study. Br J Psychiatry.1989;154:348–353.
36.
Advisory Council on the Misuse of Drugs. Consideration of Naloxone. London: Advisory Council on the Misuse of Drugs; 2012.
37.
DavisCS, WalleyAY, BridgerCM. Lessons learned from the expansion of naloxone access in Massachusetts and North Carolina. J Law Med Ethics. 2015;43(Suppl 1):19–22.
38.
Doe-SimkinsM, QuinnE, XuanZ, . Overdose rescues by trained and untrained participants and change in opioid use among substance-using participants in overdose education and naloxone distribution programs: a retrospective cohort study. BMC Public Health. 2014;14:297.
39.
GaleaS, WorthingtonN, PiperTM, NandiVV, CurtisM, RosenthalDM. Provision of naloxone to injection drug users as an overdose prevention strategy: early evidence from a pilot study in New York City. Addict Behav. 2006;31:907–912.
40.
StrangJ, PowisB, BestD, . Preventing opiate overdose fatalities with take-home naloxone: pre-launch study of possible impact and acceptability. Addiction. 1999;94:199–204.
DavisCS, CarrD. Legal changes to increase access to naloxone for opioid overdose reversal in the United States. Drug Alcohol Depend. 2015;157:112–120.
43.
DavisCS, CarrD, SouthwellJK, BeletskyL. Engaging law enforcement in overdose reversal initiatives: authorization and liability for naloxone administration. Am J Public Health. 2015;105:1530–1537.
44.
DavisCS, SouthwellJK, NiehausVR, WalleyAY, DaileyMW. Emergency medical services naloxone access: a national systematic legal review. Acad Emerg Med. 2014;21:1173–1177.
SmithSM, DartRC, KatzNP, . Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations. Pain. 2013;154:2287–2296.
